Summer School for HCPs

When: 4 Jul 2016 - 8 Jul 2016
Organiser: European Alliance for Personalised Medicine
Contact: Denis Horgan, Executive Director | phone: +32 4725 35 104 | email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

TEACH stands for Training and Education for Advanced Clinicians and HCPs and the goal is to bring young HCPs up-to-date with developments in this exciting field.

Aimed at young healthcare professionals aged 28-40, TEACH will cover topics such as monoclonal antibodies, inhibitory drugs and putting the patient at the centre of his or her own care - all within the context of personalised medicine.

The gathering will be held from 4-7 July in Cascais, Portugal, and, over the course of the four-day school, a 20-strong faculty of experts will oversee plenaries, group discussions and interactive role play sessions involving the +/- 80 HCPs enrolled on the course.

Registration is already open an there will be an ‘early bird registration’ option until May.

Read more here.

The tutors (the faculty) have been chosen from medical academic, clinical and research specialties, patient organisations and communication specialist, and you can find out more here.

Extra information for registrants and press:

About the Summer School

www.euapm.eu/about-the-summer-school.html

IPSS-R MDS Risk Assessment Calculator

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator

calculator

Click here

MDS Fact Sheet

MDS Factsheet for GPs General Practicioners

MDS Fact Sheet

Click here

Varicella Vaccine in MDS

Urgent Clarification on varicella vaccine policy

Current advice from the UK MDS Forum is not to give the Live Varicella Vaccine to patients with MDS.

Please read below correspondence between Professor Salisbury and Dr George Follows, the latter on behalf of the CLL Forum, on the varicella vaccine policy.
This is an external link to the British Society for Haematology  Click here

NICE Guideline

Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.

NICE logo

Click here

BSH Guidelines

This is an external link to the home of the British Society for Haematology (BSH). 

BSH Logo Strapline RGB

Click here